Our study validated for the first time the target-binding relationship between PSMA3-AS1 and miR-29a-3p and explored the effect of PSMA3-AS1 on PRAD cells via miR-29a-3p. This evidence concerns the gene PSMA3 and prostate adenocarcinoma.